AltrixBio has developed LuCI™ (Luminal Coating of the Intestine), an innovative oral therapy designed to replicate the metabolic benefits of bariatric surgery without the need for surgical intervention. This unique approach involves creating a temporary, non-systemic coating in the stomach and upper gastrointestinal tract, which triggers hormonal responses similar to those observed after gastric bypass surgery. By isolating the mucosa from nutrients, LuCI™ enhances incretin signaling, improves insulin sensitivity, and promotes weight loss, thereby addressing the challenges associated with type 2 diabetes (T2D) and obesity. The therapy is based on sucralfate, a well-established compound with over 40 years of clinical use, ensuring a strong safety profile and tolerability.

LuCI™ not only aims to provide an effective treatment for T2D but also has the potential for broader applications in the cardiometabolic space, including weight management and conditions like metabolic-associated steatohepatitis (MASH) and polycystic ovary syndrome (PCOS). The platform's design allows for scalability and the possibility of combining it with other therapeutic agents, enhancing its utility in various treatment regimens. With a robust patent position and an expedited regulatory pathway, AltrixBio is poised to transform the standard of care for metabolic diseases, offering a novel, convenient alternative to existing therapies.

United States

Founded in 2019, AltrixBio is a biopharmaceutical company pioneering new treatments for cardiometabolic diseases. The company builds on research from Mass General Brigham and Harvard Medical School that generated a bio-engineered potential first-in-class oral therapy for type 2 diabetes, obesity and other cardiometabolic diseases. The AltrixBio team comprises scientists, clinicians and industry leaders with deep expertise in science, operations and commercialization.

AltrixBio

Company Details